The director of this ASX company just made another sizeable share purchase

More insider buying action has failed to prop up the Polynovo share price.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points
  • Polynovo shares backtrack 4.6% to $1.14 
  • Polynovo chair, David Williams topped up his holdings through an on-market trade of close to 80,000 shares 
  • Since the beginning of May, Mr Williams has spent around $4.65 million on Polynovo shares 

In a sea of red across the ASX today, the Polynovo Ltd (ASX: PNV) share price is faring no better.

During early afternoon trade, the medical device company's shares are swapping hands at $1.14, down 4.6%.

This comes despite Polynovo announcing another sizeable share purchase from one of its directors.

For context, the All Ordinaries Index (ASX: XAO) is 0.95% in the red to 7,391.9 points.

A cool young man walking in a laneway holding a takeaway coffee in one hand and his phone in the other reacts with surprise as he reads the latest news on his mobile phone

Image source: Getty Images

Polynovo insider buying action continues

Following the recent market slump, the company's chair, David Williams has decided to take advantage of the Polynovo share price weakness.

According to its release, Polynovo advised that Mr Williams has bought 79,557 shares at a price of $1.1849 apiece. This was conducted via an on-market trade by Mr Williams' subsidiary, Lawn Views Pty Ltd.

The transaction equates to a value of more than $94,000.

Following the latest purchase, this means that Mr Williams now has over 23.24 million fully paid ordinary Polynovo shares across all holdings.

The latest buy-in reflects that a number of insiders, particularly Mr Williams believe Polynovo shares are trading at bargain levels.

It is worth noting that at the beginning of May, Polynovo shares touched a 52-week low of 83.5 cents.

It's also worth noting that Mr Williams has made a number of purchases since the beginning of May 2022. In fact, he has spent around $4.65 million over that time.

Polynovo share price summary

Despite this month's 19% gain, Polynovo shares have fallen by 55% in the past 12 months.

Year to date, its shares are down roughly 25%.

Based on today's price, Polynovo presides a market capitalisation of approximately $817.18 million.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended POLYNOVO FPO. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Devastated woman sits near smartphone on home kitchen floor troubled with loneliness.
Healthcare Shares

Which beaten down ASX healthcare stock is a better buy right now: Pro Medicus vs Cochlear shares

Which do experts prefer?

Read more »

Health professional working on his laptop.
Healthcare Shares

Already up 42% this year, Morgans says this ASX healthcare stock can continue to rocket

This broker sees big upside for this healthcare stock.

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Healthcare Shares

This ASX small-cap healthcare stock could rocket more than 50%: Morgans

Share price weakness could present an opportunity.

Read more »

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

Guess which ASX 300 stock was given a big boost from the US FDA

This healthcare stock has made a positive announcement today.

Read more »

A man in a business suit rides a graphic image of an arrow that is rebounding on a graph.
Broker Notes

Down 43% this week, are Cochlear shares now the best bargain buy of the year?

A leading analyst believes the historic selloff in Cochlear shares could present a unique buying opportunity.

Read more »

Young businesswoman sitting in kitchen and working on laptop.
Healthcare Shares

Down 50%, why I'd invest $20,000 into CSL shares

A 50% decline in a blue-chip share can signal trouble, but not always a broken story.

Read more »

Female scientist working in a laboratory.
Healthcare Shares

This ASX biotech stock could deliver 40%-plus returns Morgans says

This small company continues to kick goals.

Read more »

A man with his back to the camera holds his hands to his head as he looks to a jagged red line trending sharply downward.
Healthcare Shares

How high could Cochlear shares bounce back? Brokers disagree

Despite bad news on the earnings front this week, Cochlear shares could still deliver upside.

Read more »